NAC104 Antibody

N-Acetylcysteine (NAC) and Antibody Responses

NAC, an antioxidant and mucolytic agent, modulates B cell activation by downregulating CD40/CD27 co-stimulatory molecules and IL-4 production while upregulating IFN-γ. This shifts T cell responses toward a Th1 phenotype, suppressing T-dependent antibody induction (e.g., against Candida albicans) .

Mechanism of NAC on Antibody Production

TMEM27 Antibody (Beta Cell Marker)

A monoclonal antibody targeting TMEM27 (a pancreatic β-cell marker) enables non-invasive β-cell imaging and siRNA delivery. Key features:

• Structure: Chimeric antibody derived from hybridoma TMEM27-8/9 (DSMZ ACC2995) .

• Applications:

  • Diagnosis: Quantifies β-cell mass in diabetes .

  • Therapy: Mediates targeted siRNA delivery to β-cells .

Comparative Binding Avidity

HIV CD4-Binding Site Antibody (N6)

N6 is a broadly neutralizing antibody (bNAb) targeting HIV-1 CD4-binding sites:

• Breadth: Neutralizes 98% of 181 viral isolates .

• Potency: Median IC₅₀ = 0.038 μg/mL .

• Resistance Avoidance: Tolerates glycan clashes and missing Env contacts .

Neutralization Profile

General Antibody Databases and Resources

• PLAbDab: A database containing 150,000 paired antibody sequences, primarily from patents and literature .

• Structural Analysis: Antibody CDR sequences and frameworks are critical for antigen recognition .